<DOC>
	<DOC>NCT00314821</DOC>
	<brief_summary>To demonstrate efficacy and safety of Requip in bipolar disorder, depressive state.</brief_summary>
	<brief_title>Ropinirole in the Treatment of Bipolar Depression</brief_title>
	<detailed_description>Primary outcome will be group differences between Requip and placebo in random effects linear regression analysis. The secondary outcomes will include predictors of response, such as insight into illness, comorbid anxiety symptoms, prior course of illness, previous treatment history with antidepressants, and other relevant clinical and demographic features.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Meet DSMIV criteria for bipolar disorder, type II Current MADRS score &gt; 16 Current MRSSADS score &lt; 10 Prior to participation in this study, each subject must sign an informed consent. All patients will be required to also take at least one other moodstabilizing agent, defined as a standard agent (lithium, valproate, carbamazepine) or a novel anticonvulsant agent (oxcarbazepine, gabapentin, topiramate). If patients are not taking any of these agents on study initiation, they will be required to start one of these agents for at least two weeks before study initiation. Study inclusion criteria must be met after at least 2 weeks of treatment with one of these moodstabilizing agents. Any serious acute medical illness Any clinically serious evidence of suicidality or score of 3 or greater on suicide item on MADRS scale</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>bipolar disorder, ropinirole, depression</keyword>
</DOC>